The effect of adding buspirone to SSRIs in the treatment of obsessive-compulsive disorder

Comparison of the effectiveness of adding Buspirone to SSRI in the control of signs and symptoms of Obsessive-Compulsive Disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180303038927N1

Enrollment

Registered

2019-01-01

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: 30 patients to recieve Sertraline plus Buspirone for 3 months 50 to 200 mg Sertraline plus until 30 mg Buspirone. Intervention 2: In 30 Placebo group that only rec

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Yale Brown criteria scale for Obsessive Compulsive Disorder (OCD) > 21 score Patients will be selected according to the demographic information as: age/gender/marital status/education/job/onset age of illness/previous treatment/ age should be 18-60 The other psychiatric disease should not be existed opioid/stimulant/should not be existed Liver and Kidney diseases should not be existed

Exclusion criteria

Exclusion criteria: Yale Brown Scale below 21 scale Opioid use disorders Stimulant use disorders Liver Failure Kidney Failure

Design outcomes

Primary

Measure	Time frame
Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group 6 weeks after the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group in the end of the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group with Placebo Group six weeks after the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group with Placebo Group in the end of the treatment. Method of measurement: Yale Brown Scale.	—

Measure

Time frame

Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group 6 weeks after the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group in the end of the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group with Placebo Group six weeks after the treatment. Method of measurement: Yale Brown Scale.;Obsession scale according to Yale Brown Questionnaire. Timepoint: Comparison of Yale Brown scale in Buspirone group with Placebo Group in the end of the treatment. Method of measurement: Yale Brown Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Shirkhani

Qazvin University of Medical Sciences

m.shirkhani@Qums.ac.ir+98 28 3357 8505

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026